Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8WYQ5
UPID:
DGCR8_HUMAN
Alternative names:
DiGeorge syndrome critical region 8
Alternative UPACC:
Q8WYQ5; B2R8G1; Q6DCB2; Q6MZE9; Q6Y2L0; Q96G39; Q96GP8; Q9H6L8; Q9H6T7; Q9NRW2
Background:
Microprocessor complex subunit DGCR8, also known as DiGeorge syndrome critical region 8, plays a pivotal role in microRNA (miRNA) biogenesis. It functions within the microprocessor complex to process primary miRNA transcripts into precursor miRNA in the nucleus, crucial for gene regulation. DGCR8 specifically recognizes and binds N6-methyladenosine-containing pri-miRNAs, facilitating their processing.
Therapeutic significance:
Understanding the role of Microprocessor complex subunit DGCR8 could open doors to potential therapeutic strategies.